A 3D-microtissue-based phenotypic screening of radiation resistant tumor cells with synchronized chemotherapeutic treatment

Abstract

BackgroundRadiation resistance presents a challenge to the effective treatment of cancer. If therapeutic compounds were capable of resensitizing resistant tumours then a concurrent chemo-radiation treatment could be used to overcome radiation resistance.MethodsWe have developed a phenotypic assay to investigate the response of radiation resistant breast cancer cells grown in 3D-microtissue spheroids to combinations of radiation and established chemotherapeutic drugs. The effects were quantified by real time high content imaging of GFP detection area over 14 days. Ten established chemotherapeutic drugs were tested for their ability to enhance the effects of radiation.ResultsOf ten analysed chemotherapeutics, vinblastine was the most effective compound, with docetaxel and doxorubicine being less effective in combination with radiation. To investigate the response in a model closer to the in vivo situation we investigated the response of heterotypic 3D microtissues containing both fibroblasts and breast cancer cells. Drug treatment of these heterotypic 3D cultures confirmed treatment with radiation plus vinblastine to be additive in causing breast cancer growth inhibition. We have validated the screen by comparing radiation sensitizing effects of known chemotherapeutic agents. In both monotypic and heterotypic models the concurrent treatment of vinblastine and radiation proved more effective inhibitors of mammary cancer cell growth. The effective concentration range of both vinblastine and radiation are within the range used in treatment, suggesting the 3D model will offer a highly relevant screen for novel compounds.ConclusionsFor the first time comfortable 3D cell-based phenotypic assay is available, that allows high throughput screening of compounds with radiation therapy modulating capacity, opening the field to drug discovery.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-015-1481-9) contains supplementary material, which is available to authorized users.

Spheroid-based 3D Cell Cultures Enable Personalized Therapy Testing and Drug Discovery in Head and Neck Cancer

“…For the generation of Hanging Drops (HDs), a cell suspension of 1,000 (FaDu) or 2,000 cells (Cal27) was used in the GravityPLUS™ 3D Culture and Assay Platform (InSphero, Schlieren, Switzerland). The platform was then incubated as described previously (34). Depending on cell line, 3 (FaDu) to 5 (Cal27) days turned out to yield the best results in terms of morphology.…”

Accurate Morphology Preserving Segmentation of Overlapping Cells based on Active Contours

“…In CellProfiler, we used a mixture of a Gaussian global threshold method and an intensity-based splitting of clumped objects with object diameters in the range [25 and 35] pixels. In the MLGOC model, the preferred radius was set empirically to 17 (Fig.…”

Three‐dimensional microtissues essentially contribute to preclinical validations of therapeutic targets in breast cancer

“…3D microtissues were produced within 3 days and transferred into InSphero GravityTRAP ™ plates. Growth of six spheroids per approach was analyzed every 3 days by the high content screening system Operetta (Perkin Elmer, Waltham, MA) and quantified in maximal area of GFP‐expressing microtissue ( μ m 2 ) using the Harmony analysis Software (Perkin Elmer) . Medium was refreshed at day 6 posttransfer to assay plates.…”